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Considerable evidence points to the efficacy of CTL in clearing
viral infections, via the specific recognition of immunogenic viral
peptides in the binding groove of the MHC class I molecules
(Townsend et al, 1989). However, the efficacy of CTL responses
against tumours may be limited by a number of tumour escape
mechanisms (Bodmer et al, 1993). Many cancer cells express
tumour-associated antigens (TAAs) that can be bound on their
surface by monoclonal antibodies (mAbs) (Riethmuller and
Johnson 1992). The clinical use of mAbs as native proteins or to
direct radioactivity or toxic drugs to tumour cells has been investi-
gated extensively over the past 20 years and now antibodies to
treat lymphoma (Maloney et al, 1994), colorectal cancer
(Riethmuller et al, 1998) and ovarian cancer (Hird et al, 1993) are
entering clinical practice.
Whilst the natural antibody effector mechanisms such as
complement-mediated lysis and antibody-dependent cell-mediated
cytotoxicity (ADCC) may produce target cell damage in vivo, an
alternative of using antibodies to redirect the cellular immune
system to tumours may produce a more effective action. A number
of immunotherapeutic strategies have been described that combine
the tumour specificity of anti-tumour mAbs with these powerful
effector mechanisms of the cellular immune system. Bispecific
antibodies which cross-link tumours to receptors on T-cells (Perez
et al, 1985), natural killer (NK) cells (Weiner et al, 1996),
macrophages and neutrophils (Valone et al, 1995), and the anti-
body superantigen conjugates (Dohlsten et al, 1991) and fusion
proteins (Dohlsten et al, 1993) that link TAAs to T-cell receptors
all aim to redirect effector cells of non-tumour specificity to
tumour cells.
Here we describe a novel targeting system to deliver MHC class
I/peptide complexes to tumour cells via tumour-specific mAb,
thereby rendering the tumour cells susceptible to lysis by CTLs
which have specificity for the peptide incorporated into the recom-
binant MHC class I/peptide complex. The result of this will be to
allow efficient lysis of tumour cells of low immunogenicity by




The Daudi B-cell line (Klein et al, 1968) (MHC class I-negative)
melanoma line SK-mel-29 (Knuth et al, 1989) (HLA-A2.1-posi-
tive), and 221/A2, an HLA-A2.1-positive T-cell clone, were main-
tained in RPMI media with 10% fetal calf serum and antibiotics in
a 37°C incubator with 5% carbon dioxide. Human cytotoxic T-cell
clones 010 (specific for HLA-A2/gag 77–85 = SLYNTVATL)
(Parker et al, 1992) and 1F9 (specific for HLA-A2/melan-A 26–
35 = EAAGIGILTV) (Romero et al, 1997) were maintained in
media supplemented with 5% human serum and IL-2 100 IU ml–1.
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Summary A number of cell surface molecules with specificity to tumour cells have been identified and monoclonal antibodies (mAb) to some
of these antigens have been used for targeting tumour cells in vivo. We have sought to link the powerful effector mechanisms of cytotoxic T-
cells with the specificity of mAb, by targeting recombinant HLA class I molecules to tumour cells using an antibody delivery system. Soluble
recombinant MHC class I/peptide complexes including HLA-A2.1 refolded around an immunodominant peptide from the HIV gag protein
(HLA-A2/gag) were synthesized, and the stability of these complexes at 37°C was confirmed by enzyme-linked immunosorbent assay using
a conformation-specific antibody. MHC class I-negative lymphoma cells (Daudi) were labelled with a biotinylated mAb specific for a cell
surface protein (anti-CD20) then linked to soluble biotinylated HLA-A2/gag complexes using an avidin bridge. Flow cytometry revealed strong
labelling of lymphoma cells with HLA-A2/gag complexes (80-fold increase in mean channel fluorescence). CTL specific for HLA-A2/gag
efficiently lysed complex-targeted cells, while control CTL (specific for an HLA-A2.1-restricted epitope of melan-A) did not. Similarly, SK-mel-
29 melanoma cells were also efficiently lysed by HLA-A2/gag-specific CTL when HLA-A2/gag complexes were linked to their surface via the
HMW-MAA specific anti-melanoma antibody 225.28s. With further consideration to the in vivo stability of the MHC class I/peptide complexes,
this system could prove a new strategy for the immunological therapy of cancer. © 2000 Cancer Research Campaign
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Biotinylated complexes of recombinant MHC class I and peptide
were produced as described previously (Altman et al, 1996; Ogg et
al, 1998). Briefly, prokaryotic expression of B2M and MHC class I
heavy chain, modified by the C terminal addition of a target
sequence for the biotin ligase enzyme BirA, was followed by
inclusion body purification. Following refolding of heavy chain
and B2M around specific peptide, complexes of 45 kDa were
isolated by gel filtration, biotinylated overnight to an efficiency of
70–100% at a single lysine residue within the target sequence
peptide using BirA in the presence of ATP, Mg2+ and biotin, and
then purified by gel filtration and anion exchange.
Stability of MHC class I/peptide complexes
Complexes at 10 mg ml–1 in tissue culture media were preincubated
for 0–20 h at 37°C, before analysis by enzyme-linked immunosor-
bent assay (ELISA). ELISA plates had been coated with the mAb
W6/32 (5 mg ml–1 in carbonate buffer pH 9.6 overnight at 4°C) that
recognizes conformationally-correct MHC class I molecules
(Parham et al, 1979), then blocked (1% bovine serum albumin in
phosphate-buffered saline (PBS) for 2 h at 37°C). MHC class 
I complexes were incubated for 30 min at room temperature, 
and binding detected with rabbit anti-human b2M followed by
alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin.
Detection of the bound enzyme was by incubation with pNPP with
the absorbance at 405 nm measured in a Titertek Multiscan ELISA
reader. The plots show the mean of assays performed in triplicate.
All incubations were separated by extensive washes in PBS.
FACS analysis
Daudi cells deficient in MHC class I expression were sequentially
incubated at 4°C with biotinylated anti-CD20 (Ancell,
Nottingham, UK; mAb 2H7 (Berenson et al, 1986) 1 mg ml–1, 30
min), hen egg avidin (S.P.A., Milan, Italy; 10 mg ml–1, 10 min),
biotinylated HLA-A2/gag (10 mg ml–1, 10 min) and fluorescein
isothiocyanate (FITC)-labelled anti-MHC class I (Ancell,
Nottingham, UK; mAB 3F10 (Eisenbarth et al, 1980) 10 mg ml–1).
Parallel controls omitted one or other incubation. Cells were
washed 3 times in PBS between stages and then fixed in PBS plus
2% formaldehyde and analysed by flow cytometry.
Cytotoxicity assays
Daudi or SK-mel-29 cells were incubated with 51CrO4 at 2 mCi ml–1
for 1 h at 37°C and then sequentially incubated with the biotinyl-
ated mAbs 2H7 or 225.28s (anti-HMW-MAA) (Buraggi et al,
1985) respectively, avidin and biotinylated HLA-A2/gag
complexes as detailed above for FACS analysis. Peptide pulsed
targets cells were incubated with gag 77–85 or melan-A 26–35
peptides 0.1 mM for 1 h at 37°C. After washing, labelled target
cells were plated into 96-well round bottom plates at 2500 cells per
well, followed by human CTL at various effector:target ratios.
Following incubation at 37°C, 20 ml of supernatant was collected
and the amount of 51Cr released determined. The percentage of
cytotoxicity obtained at each effector:target ratio was calculated 
as 100 ´ (E2M)/(T2M), where E = experimental release, M =
release in media and T = release in 5% Triton X-100 detergent.
Results shown are the mean of experiments performed in dupli-
cate.
RESULTS
Biotinylated recombinant MHC class I/peptide
complexes are stable at 37°C
The effect on the stability of the recombinant MHC class I/peptide
complexes by preincubation at 37°C was demonstrated by ELISA.
The optical density obtained with samples preincubated for 0, 1, 4,
16 and 20 h is shown in Figure 2. The results demonstrate that 
the HLA-A2/gag complexes have appreciable stability in culture
media at 37°C, with an estimated half-life in excess of 24 h.
Similar results are shown for a number of other MHC class I
peptide complexes including HLA-A2/Gag3F(SLFNTVATL),
HLA-A2/Lmp2, HLA-B35/Env and HLA-B35/nef. In storage at
0.5–1 mg ml–1 at 4°C HLA-A2/gag complexes appear to be stable
for at least 12 months (data not shown).
Targeting of biotinylated HLA-A2/gag complexes to
Daudi cells demonstrated by FACS
Cells incubated with all three layers of the labelling system had
high levels of detectable MHC class I/peptide on their surface
compared to untreated Daudi cells (Figure 3). Cells treated with
only any two components of the three-step system gave fluores-
cence levels comparable to untreated cells (data not shown).
Tumour cells targeted by HLA-A2/gag complexes are
lysed by HLA-A2/gag-specific CTL
CTL clone 010 efficiently lysed HLA-A2-positive targets
(221/A2) only when these were preincubated with the HLA-
A2/gag peptide (Figure 4A). MHC class I-negative Daudi cells,
targeted with HLA-A2/gag complexes, were recognized and lysed
by this CTL clone to an equivalent degree (Figure 4A). Untargeted
Daudi cells and cells targeted with only two of the three incuba-
tions were not recognized (maximal lysis < 4% at E:T ratios of up
to 80:1). Control CTL, showing a different HLA-A2-restricted
specificity (HLA-A2/melan-A), did not lyse Daudi cells targeted
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Figure 1 Schematic representation of the three-step targeting system
delivering HLA-A2 peptide complexes to cells bearing a tumour associated
antigen. Step 1 is the delivery of a biotinylated mAb with specificity for the
tumour associated antigen. Step 2 is the delivery of avidin. Step 3 is the
binding of recombinant biotinylated HLA-A2 containing the immunogenic
peptide of viral originwith the HLA-A2/gag complexes (Figure 4B), demonstrating the
fine specificity of the targeting approach. Untreated Daudi cells
pulsed with gag peptide alone were not lysed by clone 010 (data
not shown), in keeping with their lack of endogenous MHC class I.
The ability of antibody-directed HLA-A2/gag complexes to
sensitize the melanoma cell line SK-mel-29 to lysis by HLA-
A2/gag-specific CTL line in shown in Figure 5. At all E:T ratios,
melanoma cells targeted by complexes linked to surface proteins
were lysed substantially more than controls exposed to only two
components of the three-step targeting system.
DISCUSSION
Cancer immunotherapy aimed at stimulating tumour-specific CTL
has met only limited success to date. A number of alternative
approaches using the specificity of antibody–TAA interactions to
redirect cytotoxic T-cells of non-tumour specificity to cancer cells
are currently in clinical trials. In this project we have investigated
the possibility of targeting cancer cells for lysis by virus-specific
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Figure 2 ELISA result examining the in vitro stability of HLA-A2/peptides
complexes following preincubation at 37°C. The HLA is bound by
immobilized mAb W6/32 which only recognizes conformationally correct HLA
class I and is detected by rabbit anti-human b2-microglobulin
Figure 4 A Four-hour 51Cr release assay using the HLA-A2/gag-specific CTL clone 010 and HLA-class I-deficient Daudi cell targets targeted with the three-
step delivery system. Column 1 is native Daudi cells; column 2 is Daudi cells targeted with steps 1 and 2 only; column 3 is Daudi cells targeted with steps 2 and
3 only; column 4 is Daudi cells targeted with all 3 steps of the system; column 5 is HLA-A2-positive target cells unpulsed; column 6 is HLA-A2-positive target
cells pulsed with the gag peptide. The results of duplicate experiments at effector to target ratios of 1:1, 10:1 and 80:1 are displayed. B Four-hour 51Cr release
assay using HLA-A2/gag and HLA-A2/Melan A specific CTLs against Daudi cells targeted with HLA-A2/gag complexes using the three-step system
Figure 5 Twenty-hour 51Cr release assay using the HLA-A2/gag-specific
CTL line and HLA-A2-positive SK-mel-29 cells targeted with two or all three
steps of the three-step targeting system. Column 1 is melanoma cells
targeted with steps 2 and 3 only; column 2 is melanoma cells targeted with
steps 1 and 2 only; column 3 is melanoma cells targeted with all 3 steps. The
results of duplicate experiments at effector to target ratios of 4:1, 8:1 and
16:1 are displayed
Figure 3 FACS analysis of MHC class I-deficient Daudi cells targeted with
HLA-A2 via biotinylated anti-CD20 mAb. The presence of bound HLA class I
molecules was demonstrated with an anti-HLA class I FITC-conjugated mAb.
Trace 1 native untreated Daudi cells. Trace 2 Daudi cells targeted
sequentially with mAb/avidin/HLA-A2/gag/ followed by FITC-conjugated anti-
HLA class I
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CTL using soluble MHC class I/peptide complexes. The avail-
ability of recombinant HLA class I molecules containing peptides
of predetermined specificity (Garboczi et al, 1992) and that can
incorporate a biotin binding domain (Altman et al, 1996) has facil-
itated the investigation of this new therapeutic strategy.
The hypothesis that T-cells will interact effectively with HLA
class I molecules attached to cells by an antibody bridge is
supported by previously published work. CTL can degranulate and
release cytokines on binding immobilized MHC class I/peptide
complexes (Kane et al, 1989) and streptavidin-conjugated HLA-
A2 attached to murine plasmacytoma cells via biotinylated cell
surface proteins can induce effective lysis of these cells by HLA-
A2-restricted CTL (Elliot and Eisen, 1988).
The viability of attaching recombinant MHC class I/peptide
complexes to tumour cell surface proteins was confirmed by
FACS analysis (Figure 3). The ability of CTL to recognize these
complexes and specifically lyse the targeted tumour cells was
confirmed by chromium release assay (Figures 4 and 5). Lysis of
targeted (MHC class I-negative) Daudi cells was extremely effi-
cient, comparable to MHC class I-positive targets (Figure 4A).
Hence recombinant soluble MHC classI/peptide complexes
remain fully functional when bound to tumour cells in this way.
The results from the lysis of the HLA-A2 expressing melanoma
cell line SK-mel-29 indicate that there can still be effective
targeting and interaction with T-cells in the presence of endoge-
nous class I on the surface of the target cell. The degree of cell
killing seen in this experiment is lower than in the Daudi cell line
(Figure 5 cf Figure 4). This may reflect the use of a CTL line
rather than a clone in this experiment, the higher resistance of
melanoma cells to CTL lysis, or the lower antigen density of
HMW-MAA compared to CD20. However, this experiment still
demonstrates that a tumour-specific cell surface marker (unlike
CD20) can be used to sensitize tumour cells to lysis by virus-
specific CTL by targeting with soluble MHC class I/peptide
complexes.
The feasibility of employing such a targeting system in vivo
remains to be assessed. A multi-step targeting system may not be
necessary, since tumour-specific antibodies could potentially be
conjugated to MHC class I/peptide complexes prior to administra-
tion. Nevertheless, it is apparent that multi-layer antibody–avidin
delivery systems are viable in clinical research (Magnani et al,
1995), with the high affinity (10–15 M) non-covalent bond formed
between biotin and avidin being exploited in antibody targeting
systems to deliver effector mechanisms including radioactive
isotopes (Paganelli et al, 1991) and tumour necrosis factor (Moro
et al, 1997). The immunogenicity of avidin or other components
of the targeting system may limit repeated use; however, such
responses might be minimized by transient immunosuppression
(Ledermann et al, 1991). Alternative less immunogenic two-step
delivery systems, such as the recently described calmodulin–
calmodulin binding peptide system (Neri et al, 1996), may also
become available clinically.
Regardless of the chemistry used, however, the stability of the
MHC class I/peptide complexes at 37°C will need further investi-
gation, as the rate of degradation observed may preclude use in
vivo. Although our data show good stability over 20 h, this is
unlikely to be sufficient for clinical purposes. Fortunately, it is
likely that complex stability will be significantly improved by
either protein engineering methods (Toshitani et al, 1996; Lone et
al, 1998) or chemical modification (Wilson et al, 1995), and new
methods for synthesizing MHC class I/peptide complexes are
already being assessed in this regard (unpublished data). Whilst
there is no experience to date on the administration of recombinant
HLA molecules in humans, it seems likely that they may circulate
freely after administration, since endogenous soluble MHC class I
molecules are readily detectable in healthy serum (Davies et al,
1989). Further, since monomeric MHC class I/peptide complexes
have a low affinity for the T-cell receptor (Schneck et al, 1989;
Altman et al, 1996), binding to specific CTL during circulation,
which might cause sequestration of complexes in lymphoid areas,
is likely to be minimal. Administration of MHC class I/peptide
complexes in animal experiments has not proven toxic (Terness et
al, 1996). Work is currently in progress to examine the pharmaco-
kinetics of the current system in preclinical models.
The experiments presented here used complexes containing a
peptide from the gag protein of the HIV virus, which would not
necessarily be ideal for in vivo application. For clinical work,
MHC class I molecules refolded around peptides from the
Epstein–Barr virus (EBV) may be a more effective choice. In EBV
infection, CTL specific for the RAKFFQLL epitope of the lytic
protein BZLF1 can account for up to 44% of peripheral blood
CD8+ cells in the acute phase. Data suggest the anti-EBV CTL
response persists at significant levels for years after primary infec-
tion, and may be repeatedly re-activated during life (Callan et al,
1998), providing natural boosts in the frequency and activation of
CTL which might be re-targeted at tumours.
Alternatively, novel immunogenic peptides or alloreactive HLA
molecules may induce strong effector function. In vivo cytokine
support with interleukin-2, which up-regulates T-cell activity, or
the infusion of antigen-specific CTL expanded ex vivo are other
modifications which may also aid clinical utility.
Finally it must be noted that whilst many tumour types express
TAAs, heterogeneity in the level of expression does occur, so
some tumour cells may not be targeted by antibody and lysed
directly. However, in vitro data from the analogous antibody-
superantigen system shows that the high local levels of cytokines
released by activated T-cells can lead to the death of untargeted
bystander tumour (Dohlsten et al, 1995), it is likely that similar
effects will occur in a targeting system using MHC class I/peptide
complexes. Similarly, it is possible that the presence of activated
CTL releasing cytokines in the tumour may lead to enhancement
of a specific anti-tumour immune response.
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